Malignant melanoma is one of the most aggressive and therapy resistant types of cancer. In 2011, more than 8,700 new cases of melanoma diagnosed and 3,368 deaths caused by this cancer were documented in Russia. In contrast to many other cancers, the mortality caused by melanoma is still increasing, with almost 30% incre ment in registered deaths during the last decade in Russia [1] . The same tendency takes place in other countries [2, 3] . This lack of progress in the treatment of malignant melanoma is caused in part by the high invasiveness of melanomas, thus making surgical treatment lowly effec tive. Conventional chemotherapy of this cancer is also inefficient [4] . Median survival of patients with non cutaneous metastasis is less than one year, with a 5 year survival not more than 10% even in developed countries [5] . Thus, the search for specific markers of this disease, especially specific surface markers [6] and altered signal ing pathways, for development of immunotherapy and different types of targeted therapy [4, 7] is of great inter est. ISSN 0006 2979, Biochemistry (Moscow), 2013, Vol. 78, No. 11, pp. 1228 1237. © Pleiades Publishing, Ltd., 2013. Published in Russian in Biokhimiya, 2013, Vol. 78, No. 11, pp. 1564 1575 
BIOCHEMISTRY (Moscow) Vol. 78 No. 11 2013 Melanoma. Melanomas develop as a result of malig nant transformation of pigment cells called melanocytes, which are localized in the epidermis immediately over the basal membrane, rarely in derma and choroid. Skin melanocytes compose 10 25% of basal layer cells of the epidermis [8] and are the cells producing melanin in response to ultraviolet radiation with subsequent melanin accumulation in melanocytes and surrounding ker atinocytes [9] . Primary melanomas are usually revealed in skin, but ocular localization of melanoma also occurs quite often (around 10% of cases), and rarely melanomas localize on mucous membranes [10] . In its early stage of development (the stage of radial growth) the tumor remains localized, thus surgical treatment yields good results. As soon as the cells able to penetrate into deeper layers of skin appear, the tumor switches to a vertical growth stage known for its high metastatic potential and poor prognosis [11] .
Malignant transformation of melanocytes to melanoma is associated with production of growth factors and expression of receptors that are absent on and are not produced by normal melanocytes. This list of growth fac tors includes basic fibroblast growth factor, transforming growth factors alpha and beta, platelet derived growth factor, interleukins, growth hormone, granulocyte macrophage colony stimulating factor, stem cell factor, and some other [12] . Melanoma is able to produce not only the different growth factors and cytokines, but also their receptors, thus enabling self regulation of tumor cell behavior.
The most frequent genetic alterations revealed in melanoma cells are: amplification of apoptosis inhibitor Bcl 2 (>90% cases), activation of one of the key cell cycle regulators mTor (mammalian target of rapamycin, 67 77%), mutagenic constant activation of MAPK/ ERK signaling pathway regulator BRAF (v Raf murine sarcoma viral oncogene homolog B1, 66%) kinase [13] , enhanced expression of adaptor protein NEDD9 (neural precursor cell expressed, developmentally down regulat ed 9) promoting cell invasion (50 60%) [14, 15] , and loss of CDKN2A (cyclin dependent kinase inhibitor 2A) [15] . While attempts to inhibit the first two factors were poorly effective clinically, the use of BRAF inhibitors for melanoma treatment seems to be encouraging [16, 17] . Also, attention of researchers specializing in investiga tion and treatment of melanomas has being focused for more than three decades on α melanocyte stimulating hormone (α MSH) receptor expression on melanoma cells [18] . The specific interest is that the expression of this receptor, a member of a melanocortin receptors fam ily (MC1R, melanocortin 1 receptor), is usually upregu lated in melanoma cell lines as well as in melanomas [19 25] . The fact that immunocytochemical staining of slides of different tissues reveals enhanced MC1R expression in human melanomas that is significantly higher than in any healthy tissue [23] is also important for diagnostics and potential treatment. However, the diagnostics relying on MC1R becomes somewhat complicated due to the usual secretion of proopiomelanocortin peptide gene products (adrenocorticotropic hormone, melanocyte stimulating hormones, β endorphin, etc.) by melanoma cells, and moreover their production rate usually correlates with the melanoma stage [11, 21] . Endogenous ligands to MC1R that are presented in tissues can affect the inter actions of diagnostic drugs because of their competition for the receptor as well as a decrease in cell surface recep tors due to the internalization of hormone-receptor complexes.
α MSH also stimulates the division of normal melanocytes when they are affected by mitogens like basic fibroblast growth factor and phorbol esters [26] . The ability of α MSH to enhance proliferation and to increase (in some cases) the number of cell surface recep tors can seemingly lead to stimulation of melanoma growth. An increase in α MSH and MC1R expression in keratinocytes and fibroblasts probably promotes the development of an early melanoma stage [27] .
Melanocortin 1 receptor. Receptor for α MSH (MC1R) belongs to the melanocortin receptors group, which also includes four other receptors with 40 60% homology. All these receptors can bind to adrenocorti cotropic hormone (ACTH) and all except one (MC2R) can bind to α MSH. The other melanocyte stimulating peptides (β and γ MSH) also can bind to MC1R and MC(3 5)R evoking a biological response; however, their affinity for these receptors is significantly lower. MC2R is the specific receptor for ACTH only [28] . Melanocortin receptors with their polypeptide chain passing through the plasma membrane seven times belong to the huge G protein coupled receptors (GPCR) family that interact with G proteins. Melanocortin receptors are the smallest GPCR members, having short N and C termini and extracellular second loop. All five MCRs are functional ly connected to adenylate cyclase, and their action is mediated mostly by cAMP dependent signaling pathway activation [28] . The activation of the MC1R signaling pathway in melanocytes stimulates tyrosinase activity, which is the rate limiting enzyme of melanin production [29] (Fig. 1, see color inset ). Melanin accumulates in specialized cellular organelles called melanosomes, which are transported along dendritic spines to the extra cellular space to be seized there by neighboring ker atinocytes. One melanocyte contacts and provides with melanin approximately 35 keratinocytes [30] . Ultraviolet radiation induced MC1R activation in skin is mediated by an increase in synthesis and release of melanocortin peptides by melanocytes and keratinocytes [31 33] . In response to ultraviolet radiation, keratinocytes also pro duce higher amount of endothelin 1, which is a paracrine mitogen for melanocytes that enhances MC1R expression in these cells [34, 35] . α MSH mediated response of melanocytes lasts a long time, as the hor BIOCHEMISTRY (Moscow) Vol. 78 No. 11 2013 mone leads to enhancement of the receptor mRNA syn thesis, obviously via increasing cAMP level [35] , thus resulting in higher level of MC1R expression [36 38] . Similar effects can be seemingly observed in some cases in melanoma cells [38, 39] . Moreover, melanoma can signif icantly enhance MC1R expression in neighboring cells [40] .
MC1R endocytosis and intracellular distribution. Like the other GPCR, newly synthesized MC1R is trans ported to the surface of its expressing cells. Interestingly, the cell surface melanocortin receptors exist in pre organized homo and heterodimeric forms. Moreover, this dimerization does not depend on ligand-receptor binding [41] . MC1R dimerization is mediated by both noncovalent interactions and formation of disulfide bonds between monomers [42] . Apparently, heterodimer ization between mutant and normal MC1R forms can be responsible for dominant negative action of some MC1R alleles [43] .
Incubation of cells with MC1R agonists promotes internalization of the ligand-receptor complexes [44] , which is one of the ways to decrease the activity of the agonist stimulated processes. In the case of MC1R, response desensitization is realized via two members of the GPCR kinases (GRK) family -GRK2 and GRK6 [45, 46] . Agonist binding to MC1R results not only in activation of the receptor itself, but it also activates its kinases. Due to this fact, the initial hormone induced cAMP level increase in cells goes through a maximum and starts decreasing. While one of these kinases (GRK2) can decrease constant MC1R activity, which does not depend on agonist activation [45] , the other (GRK6) mediates agonist dependent internalization of the recep tor via phosphorylation of its cytoplasmic C terminus amino acids [46] . Recent findings reveal that this inter nalization is regulated by binding of arrestins to the cyto plasmic part of the receptor [47] . Arrestin β 1 (ARRB1) and arrestin β 2 (ARRB2) are involved in this process. ARRB2 promotes MC1R endocytosis and inhibits ago nist dependent cAMP production, while ARRB1 does not affect these processes but does compete with ARRB2 for binding to MC1R [47] (Fig. 1) .
Immunochemical staining of melanoma cells also reveals perinuclear localization of MC1R in these cells and keratinocytes, neighboring melanoma [40, 48] , indi cating the endocytosis of α MSH-receptor complexes. Interestingly, immunocytochemical staining of placental trophoblasts for MC1R demonstrates generally intranu clear staining [49] ; therefore, under these conditions MC1R can be transported actively to the nucleus.
Interaction of MC1R with intracellular regulators. In addition to interaction with Gα s and subsequent activa tion of adenylate cyclase, MC1R interplays also with a number of other intracellular proteins. Like the other melanocortin receptors, MC1R can interact with the small accessory protein MRAP (melanocortin 2 receptor accessory protein) and with its homolog MRAP2. MC1R interaction with these transmembrane proteins decreases cAMP production, mediated by melanocyte stimulating ligands, but in contrast to some other melanocortin receptors (first of all, MC2R) it does not affect the trans port to the plasma membrane of newly synthesized MC1R [50] .
Additionally, MC1R can interact with a number of other cellular regulatory proteins, thus affecting the receptor mediated signaling. One of these proteins is attractin, a coreceptor for the interaction of the α MSH antagonist ASIP (agouti signal protein) with MC1R [51] . Another is ubiquitin E3 ligase with RING domain (real interesting new gene) -MGRN1 (mahogunin RING finger 1). This intracellular protein decreases agonist receptor activation by competing with the MC1R effec tor Gα s mediating adenylate cyclase activation [52] (Fig.  1) .
Regulation of MC1R expression. The regulation of MC1R expression in mouse and human melanoma cells is quite different. Agonist mediated internalization of melanocortin receptors into B16 mouse melanoma cells results in the appearance of labeled agonist in the lysoso mal fraction, which can be revealed as early as 30 min after the start of incubation [44] . The endocytosed recep tor in these cells does not recycle to the cell surface, with its mRNA production downregulation lasting for a long period of time. Agonists mediated downregulation of cell surface receptors is prominent in mouse melanoma cell lines (B16, Cloudman S91 melanoma). Incubation of human melanoma cell lines with agonists either has neg ligible effect, or it results finally in highly increased num ber of their surface receptors due to enhanced MC1R expression [39, 53] .
Generally, the MC1R gene expression regulation scheme in melanocytes and melanoma cells clearly includes the following steps: melanocortin peptides stim ulate Gα s connected MC1R, resulting in activation of adenylate cyclase, enhancement of cAMP production, activation of protein kinase A, and CREB (cAMP responsive element binding protein) phosphorylation. Phosphorylated CREB binds to CRE (cAMP responsive element) of microphthalmia transcription factor promot er, provoking protein MITF (microphthalmia transcrip tion factor) expression. MITF, in turn, interacts with M boxes of a number of other promoter areas resulting in activation of synthesis of MC1R, tyrosinase, tyrosinase related proteins 1 and 2, and probably some other pro teins. In turn, an increased level of MC1R in the cell can enhance the above mentioned cascade. MITF driven activation of gene expression leads to chromogenesis, proliferation, and inhibition of apoptosis of the melanocytes [12, 54] . The release of melanocortin pep tides may be another factor providing positive feedback during activation of melanocytes via MC1R, because human melanocyte melanosomes contain both prohor mone convertases, which are necessary for proopiome lanocortin cleavage, and its cleavage products -MSH and ACTH [55] .
Recently, another possible mechanism of MC1R regulation on the transcriptional level by intergenic splicing was revealed [56] . The authors pointed out the complicated atypical polyadenylation site of the MC1R gene that makes intergenic splicing between MC1R and the closely downstream located β III tubulin (TUBB3) gene possible. As a result, in addition to normal MC1R, two variants of MC1R-TUBB3 are produced, with only one of them located on the cell surface. α MSH can shift the ratio of these splice variants to MC1R-TUBB3 that are significantly less potent for increasing cAMP level.
MC1R expression in tissues. MC1R expression, as well as the expression of all melanocortin receptors in normal tissues, is rather low, with the most prominent expression found in melanocytes. Other melanocortin receptors are expressed mostly in the central nervous sys tem (MC3R, MC4R), adrenal cortex (MC2R), gastroin testinal tract (MC3R), lymphocytes, and exocrine glands (MC5R) [57] .
In normal human skin, MC1R can be detected immunohistochemically in the melanocytes of hair folli cles, sweat and sebaceous glands, but not in the ker atinocytes and most interfollicular epidermal melanocytes. When a tumor appears, the keratinocytes adjacent to primary melanoma are stained intensively with anti MC1R antibodies [40, 58] with a gradient in immunocytochemical staining increasing towards the tumor [40] .
Among the skin cells primarily neighboring melanoma melanocytes, keratinocytes [59] and vascular endothelial skin cells [60, 61] were shown to express MC1R. It is worth noting that in most cases MC1R expression level in normal skin cells is at least one order of magnitude lower than in melanocytes, and it clearly has no physiological significance [62] . Moreover, in most cases with MC1R being detected only by RT PCR, the radioligand method fails to reveal any melanocortin receptor [62] . In other tissues, MC1R is present in scat tered neurons of gray substance in the brain, on macrophages and monocytes, Leydig cells in testicle, lutein cells, placenta trophoblasts, and also on astrocytes [59] . Immunohistochemical staining demonstrates that MC1R expression level in melanoma is much higher than in all normal tissues [23] . Still significantly less than in melanoma, but relatively high MC1R staining was revealed in the adrenal medulla. In monocytes, MC1R expression can increase in response to different cytokines, but it also remains much less than its expres sion on melanoma cells [23] . Thus, the summarized data available to date [19 25] clearly demonstrates that MC1R can be regarded as melanoma marker. Moreover, due to its endocytic surface receptor nature, MC1R can also be regarded as a promising agent for targeted intracellular drug delivery into melanoma cells. The elucidation of the interrelationships between MC1R expression and melanoma development has great importance.
Role of MC1R in melanoma formation, development, and prevention. MC1R is a key factor in skin protection from ultraviolet radiation, thus playing several roles in the melanocyte transformation process. On one hand, as mentioned above, MC1R activation is obviously involved in proliferation of melanoma cells, and on the other hand the same activation as well as elevated α MSH produc tion, are factors protecting melanocytes and other cells from ultraviolet radiation due to induction of melanin synthesis, which absorbs light and also acts as an antioxi dant [9] . Therefore, normal functioning of this pathway is the main factor preventing melanoma formation. Alterations in this functioning result in change in eume lanin (brown/black melanin subtype) production by melanocytes. This change shifts eumelanin to pheome lanin (yellow/red melanin pigment subtype) ratio deter mining, in particular, skin color. MC1R gene polymor phism is seemingly one of the key factors determining the variety of human skin pigmentation [63] . At least 85 allel ic MC1R gene variants are known to date [64, 65] . Some of these mutations, especially those determining red hair, are connected with an increased risk for melanoma [43, 65, 66] .
MC1R expression level is connected with melanoma cell migration: the higher the level, the higher the migra tion ability of cells is [67] . MC1R decreases the activity of stress response by p38 MAPK kinase, increasing the expression of syndecane 2, which is involved in increas ing melanoma cell motility. On the contrary, the addition of α MSH decreases the cell mobility.
Additionally, MC1R activation, as already men tioned, evokes an increase in MITF expression in melanocytes, which is involved in realization of the RAS/RAF/MEK/ERK signaling pathway and promotes cell proliferation and survival [13, 68] . It is worth men tioning that MC1R and the RAS/RAF/MEK/ERK pathway are also connected more directly ( Fig. 2 ; see color insert). MC1R activation can result not only in increase in cAMP level, but also in transactivation of stem cell growth factor receptor c KIT, probably via Src kinase [69] , which in turn leads to activation of extracel lular regulated kinases ERK1 and ERK2 [69, 70] . Several MC1R variants possessing red hair causing mutations loose the ability for hormone mediated cAMP level increase but retain the ability for activation of ERK [70, 71] .
Summarizing the available data, one can conclude that MC1R expression on melanoma cells is not only a peculiarity reflecting the origin of these tumors, but also is directly connected with activation of cell division and metastasizing ability. The higher the expression of this receptor, the more frequent cell division occurs, leading to accumulation of cells overexpressing MC1R within the tumor. Thus, ligands for this receptor can be regarded as suitable components for the design of diagnostic agents and systems for targeted delivery to melanoma cells. Melanocortin receptors, and MC1R in particular, are notable for the existence of a number of natural agonists and antagonists regulating the functioning of the effector systems associated with these receptors.
Natural ligands for melanocortin receptors. Four different natural ligands (ACTH and α , β , and γ MSH) activating melanocortin receptors and initiating the whole chain of subsequent intracellular processes originate from the same progenitor polypeptide, pro opiomelanocortin, having a molecular weight more than 30 kDa [72] . Posttranslational cleavage of this peptide results in a large number of biologically active peptidesmelanocortins, β lipotropic hormone, and β endor phin. The formation of different proopiomelanocortin derivatives is tissue specific and depends on the activity of prohormone convertases. Prohormone convertase 1 activity promotes formation of ACTH and β lipotropin along with the N terminal peptide. Further proteolysis of ACTH by prohormone convertase 2 yields α MSH. β Lipotropin cleavage gives γ lipotropin, which is cleaved in turn to produce β MSH and β endorphin. Proteolytic cleavage of the N terminal proopiome lanocortin fragment gives γ MSH [28] . All the melanocortin peptides contain the same conservative sequence His Phe Arg Trp. The somewhat longer pep tide Met Glu His Phe Arg Trp Gly, which is a part of α and β MSH and of ACTH, is apparently important for activation of melanogenesis. The C terminal tripep tide of α MSH determines its antiinflammatory and immunosuppressive effects [72, 73] . However, the recep tors determining these effects of α MSH differ from the receptors inducing melanogenesis in melanocytes in both the effective α MSH concentration range and amino acid sequences responsible for the specific effect. These data suggest the presence on immune cells of an additional receptor different from MC1R that mediates effects of α MSH on the immune system [72, 73] . A possible intracellular pathway for implementation of this effect of α MSH is inhibition of NF κB nuclear translo cation via inhibition of I κB phosphorylation by its kinase, with subsequent prevention of proteasomal degradation of I κB [73] .
Production of melanocortin peptides is highest in the anterior pituitary; however, these peptides are widely pro duced also in other tissues (adrenal glands, intestinal neu rons, skin), where their function is rather paracrine than endocrine [73] . Melanomas are characterized by enhanced expression of proopiomelanocortin. This can probably be attributed to upregulated expression of corti cotropin releasing hormone and its receptor in these tumors [21] . However, there can be another explanations, as proopiomelanocortin expression is also regulated by other pathways, for example via the JAK2/STAT3 regu latory pathway, which is activated by leukemia inhibitory factor [74] .
α MSH is a 13 amino acid peptide. Its amino acid sequence is the same for many mammals -human, mouse, cattle, etc. α MSH can bind to four human melanocortin receptors (except for MC2R), but it has the highest affinity and specificity for MC1R, possessing 260, 5500, and 47,500 times lower affinities for MC3R, MC4R, and MC5R, respectively. It is also worth noting that human MC1R needs lower α MSH concentrations for its activation than does mouse MC1R [36] .
The presence of the natural melanocortin receptor antagonists, agouti signaling protein (ASIP) and agouti related protein (AGRP), is an interesting feature of the melanocortin receptors system. The former binds to MC1R and MC4R, while the latter is an antagonist of MC3R MC5R activation. ASIP is a concurrent inhibitor of α MSH on melanocytes, and it enhances acute inflammatory reactions [72] . As already mentioned above, this ligand also has another receptor -attractin; binding to this receptor also affects skin pigmentation [75] . Another antagonist of α MSH capable of MC1R binding and preventing cAMP level increase in melanocytes and the subsequent biological effects is β defensin 3 (BD3) [66, 76] .
Development of diagnostic and therapeutic agents based on α α MSH and its analogs. The identical sequence of α MSH (Ac Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val NH 2 ) shared by human, mouse, and a number of other mammals is one of the advantages of utilizing this hormone for drug development. Therefore, α MSH is both a useful model and a perspec tive agent for subsequent therapeutic use for targeted drug delivery into cancer cells. This ligand has already been extensively used for development of different agents for specific delivery into melanoma cells (Table 1) .
The amount of MC1R on cultivated human and mouse melanoma cells varies from a few hundreds to tens of thousands [90 92] , with up to a few thousand particu larly on human melanoma cells [91, 92] , which is signifi cantly less than the amount of most surface proteins. Therefore, when exploiting this receptor in therapeutic applications, the selectivity of delivery and efficacy of affecting the intracellular targets are the guarantees for successful therapy of melanoma in vivo. As an example of enhanced efficacy, one can mention the delivery of a pho tosensitizer that generates a large amount of reactive oxy gen species upon irradiation in the nucleus, which is the most vulnerable compartment of the cell. Selective trans port into the nuclei of the necessary type of target cells can be achieved by creation of multifunctional modular transporting systems [93, 94] . Exploiting this principle for delivery of the photosensitizer bacteriochlorin p into mouse melanoma cells made it possible to achieve more than two orders of magnitude enhanced cytotoxicity of BIOCHEMISTRY (Moscow) Vol. 78 No. 11 2013 the photosensitizer for mouse melanoma B16 F1 cells [84, 85] .
It is worth noting that the ability to bind the recep tor by itself may be insufficient for action on tumor cells in vivo. For example, the interaction of gold nanoparti cles coated with polyethylene glycol modified with MC1R binding peptides with transplanted melanoma differed depending on the ability of the peptide to initi ate receptor mediated endocytosis [95] . Nanoparticles conjugated with an MC1R agonist peptide that is an α MSH analog demonstrated better tumor retention due to receptor mediated internalization, than similar nanoparticles with a peptide derived from ASIP relative protein, which resulted in only binding without subse quent internalization of nanoparticles. Agonist coated particles not only internalized inside the cells, but were also subjected to transcytosis and better tissue penetra tion, finally yielding 2 fold enhanced accumulation in the tumor.
Considering that metastasizing melanoma is the most dangerous melanoma type, the synthesis of α MSH analogs and radiotherapeutics based on these peptides is one of the most intensively studied areas in the develop ment of melanoma diagnostic tools. A number of recent review articles [96 99] 64 Cu [122, 123] , and 86 Y [122] for positron emission tomography (PET) diagnostics. Gene therapy using Na I symporter (NIS) is another approach exploiting MC1R specific ligands [124] . MC1R specific peptide inclusion into polyplexes -nanoparticles con sisting of a polycation and transferred plasmid DNA, results in significantly improved mouse melanoma trans fection in vivo, enabling melanoma cells to accumulate intravenously injected 123 I, an isotope suitable for SPECT.
MC1R mediated delivery can be exploited not only for diagnostics. There have been several studies on thera py of experimental mouse melanomas to date that point to the feasibility of this approach (Table 2) .
Radionuclides emitting sufficiently high linear energy transfer (LET) radiation, specifically α particles with very high LET along with the short range limited up to few cell diameters, demonstrate high therapeutic effi cacy in model experiments [126] . β Emitters can be use ful for the treatment of larger tumors, but these may also damage neighboring healthy tissues. Auger electron emitters characterized by high LET along with ultra short (usually less than 0.5 μm) range in tissues can be useful for eliminating single melanoma cells and micrometastasis if delivered into the nuclei of target cells [130] . Moreover, non isotope methods of melanoma treatment based on MC1R selectivity, such as photody namic therapy and suicide gene therapy, have therapeu tic potential as well. For example, the photosensitizer bacteriochlorin p conjugated to modular transporter DTox HMP NLS MSH, delivered into the cell nuclei of experimental mouse melanomas, inhibits tumor growth by 80 98% and increases survival 1.6 2.5 fold after a course of photodynamic therapy [86, 87] . Incorporation of a peptide highly specific for MC1R into a synthetic gene delivering construct resulted in signifi cantly improved melanoma suicide therapy using poly plexes carrying the Herpes simplex virus thymidine kinase gene [128] . Much experience in development of highly selective ligands for a specific type of melanocortin receptor, either consisting of natural amino acids [129, 131] or containing various synthetic analogs [100, 132 134] has accumulated to date. The use of these ligands can enhance the speci ficity of delivery into melanoma cells and decrease side effects.
Summarizing the data about melanocortin receptors and their expression in melanoma cells available to date, one can conclude that MC1R is a specific marker of melanoma cells and, in some cases, of the cells neighbor ing this tumor. MC1R expression in melanomas is usual ly higher than in any normal tissues, and ligands to this receptor can internalize specifically into the cells, thus creating the prerequisites for designing effective targeted diagnostic and therapeutic agents based on ligands for MC1R. 3 13 , peptide cyclized by rhenium via 3, 4, and 10 cysteine residues, truncat ed (3 13), and modified by α MSH at amino acids indicated by the upper indexes; DOTA, 1,4,7,10 tetraazacyclododecane 1,4,7,10 tetraacetic acid, a chelator; PEI, polyethyleneimine; PEG, polyethylene glycol; MC1sp, peptide with sequence (SSIISHFRWGKPV) high ly specific for MC1R [129] .
